Skip to content

Psilocybin: all studies

Page 241 of 440: studies 2,401 to 2,410 of 4,400, newest first. Back to the psilocybin overview

Research

Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019.

Addictive Behaviors Reports December 1, 2022 Claire A Walsh, Ofir Livne, Dvora Shmulewitz et al. 34 citations

Information on time trends in use of different plant-based hallucinogens is lacking. The current study used nationally representative U.S. data to assess overall and age-specific time trends in the prevalence of lifetime and 12-month use of plant-based hallucinogens and dissociative agents. Participants were respondents aged ≥ 12 years (N = 1,006,051) from the National Survey on Drug Use and...

Set and setting in microdosing: an oft-overlooked principle.

Psychopharmacology December 1, 2022 Ido Hartogsohn, Rotem Petranker 22 citations

The use of psychedelics for medical and recreational purposes is rising. Contextual factors such as expectancy, intention, and sensory and social environment (set and setting) are widely recognized as moderating the effects of these substances. Nevertheless, clinical trials of microdosing - the ingestion of small, sub-hallucinogenic doses of psychedelics - rarely report their set and setting....

Psychedelic-Assisted Therapy for People with Eating Disorders.

Current Psychiatry Reports December 1, 2022 Natalie Gukasyan, Colleen C Schreyer, Roland R. Griffiths et al. 29 citations

A growing body of research suggests psychedelic-assisted therapy (PAT) may be safe and effective for a variety of mental health conditions. Among these, eating disorders have been a recent target of interest. This review provides an up-to-date summary of the potential mechanisms and use of PAT in people diagnosed with eating disorders, with a focus on anorexia nervosa. Classic psychedelics may...

DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites

Applied and Environmental Microbiology November 29, 2022 Virginia Ramírez-Cruz, Giuliana Furci, Paul Stamets et al. 29 citations

The therapeutic use of psilocybin, the active ingredient in “magic mushrooms,” is revolutionizing mental health care for a number of conditions, including depression, posttraumatic stress disorder (PTSD), and end-of-life care. This has spotlighted the current state of knowledge of psilocybin, including the organisms that endogenously produce it.

Considerations in assessing the abuse potential of psychedelics during drug development

Neuropharmacology November 28, 2022 Steven Galati, Dominic Chiapperino, Silvia N. Calderon et al. 14 citations

The recent increase in clinical research on the potential therapeutic uses of classic psychedelics has prompted the need to revisit the assessment of the abuse potential of these drugs. The term "classic psychedelic" is used in this manuscript to describe serotonergic 5-HT2A agonists that alter perception, cognition, and mood (i.e., psychedelic effects) and that are currently controlled in...

DOI: 10.1016/j.neuropharm.2022.109352 (opens in new tab) Psilocybin Substance abuse Schedule Psychotherapist +1

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids

International Journal of Molecular Sciences November 15, 2022 Klára Gotvaldová, Jan Borovička, Kateřina Hájková et al. 50 citations

Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their concentration variability in wild-grown mushrooms. This article aimed to determine the PSB, psilocin (PS), baeocystin (BA), norbaeocystin (NB), and aeruginascin (AE) concentrations in a large sample set of mushrooms belonging to genera previously...

DOI: 10.3390/ijms232214068 (opens in new tab) Psilocybin Tryptamines Mushroom Agaricales +4

Experts assess role of therapists in psychedelic‐assisted therapy

Mental Health Weekly November 5, 2022 Valerie A. Canady

Acknowledging the barrage of research, media attention and capital investment focused on psychedelic compounds and the race to reach U.S. Food and Drug Administration (FDA) approval for such currently illegal drugs as psilocybin, nearly two dozen experts have weighed in on a new report that, among other things, calls attention to the critical role they said therapists play in the...

Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.

Pharmacology & Therapeutics November 1, 2022 Sanket B Raut, Padmaja A Marathe, Liza Van Eijk et al. 62 citations

Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options. Current treatment guidelines recommend psychotherapy as first line management with only two drugs, sertraline and paroxetine, approved by U.S. Food and Drug Administration (FDA) for treatment of PTSD. These drugs have...

Five new species of Inosperma from China: Morphological characteristics, phylogenetic analyses, and toxin detection

Frontiers in Microbiology October 31, 2022 Sai-Nan Li, Fei Xu, Pan Long et al.

Many species of Inosperma cause neurotoxic poisoning in humans after consumption around the world. However, the toxic species of Inosperma and its toxin content remain unclear. In the present study, we proposed five new Inosperma species from China, namely, I. longisporum, I. nivalellum, I. sphaerobulbosum, I. squamulosobrunneum, and I. squamulosohinnuleum. Morphological and molecular...

The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?

Cureus October 31, 2022 Arafath Mohamed, Shehla Touheed, Muzammil Ahmed et al. 11 citations

Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is psychotherapy, according to current treatment guidelines. However, PTSD continues to be a chronic condition even after psychotherapy, with high psychiatric and medical illness rates. There is a dire need...